About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LCZ 696

Company: Mayo Clinic
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 26 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

26 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Recruiting NCT NCT04055428

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Not yet reported University of Alabama at Birmingham 200 participants Est. completion 2027-05-31 1 site

Cardiovascular disease Other conditions: Diabetes Mellitus, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
View official trial listing →
Recruiting NCT NCT04191681

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

Not yet reported The Cleveland Clinic 50 participants Est. completion 2022-12 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT04971720

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Not yet reported, Not yet reported University of Alabama at Birmingham 160 participants Est. completion 2027-01-01 1 site

Cardiovascular disease Other conditions: Obesity, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
View official trial listing →
Recruiting NCT NCT05194111

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

Not yet reported, Not yet reported Virginia Commonwealth University 70 participants Est. completion 2028-11-30 1 site

Heart failure Other conditions: Heart Dysfunction
View official trial listing →
Recruiting NCT NCT05465031

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Not yet reported Silesian Centre for Heart Diseases 600 participants Est. completion 2029-02 4 sites

Heart failure Other conditions: Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents, Sacubitril/Valsartan, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Molecular Mechanisms of Pharmacological Action, Cardiac Toxicity, Cancer, Therapy-Related, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
View official trial listing →
Recruiting NCT NCT05498675

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Beijing Friendship Hospital 180 participants Est. completion 2027-06-30 1 site

Other conditions: Sacubitril/Valsartan, Hypertension, Obesity
View official trial listing →
Recruiting NCT NCT05508035

The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

Not yet reported John Paul II Hospital, Krakow 488 participants Est. completion 2028-12 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT05553886

S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction

Not yet reported Shenzhen People's Hospital 5 participants Est. completion 2026-12-31 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT05764057

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Not yet reported Assistance Publique - Hôpitaux de Paris 450 participants Est. completion 2026-10-12 1 site

Other conditions: AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
View official trial listing →
Recruiting NCT NCT06218199

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Not yet reported Heart Center Research, LLC 80 participants Est. completion 2026-12-31 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT06283420

Metabolic Response to the Initiation of Heart Failure Therapy

Vojtech Melenovsky, MD, PhD 120 participants Est. completion 2026-12-20 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT06643819

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Not yet reported Chong Kun Dang Pharmaceutical 324 participants Est. completion 2026-12-31 1 site

Other conditions: Essential Hypertension
View official trial listing →
Recruiting NCT NCT06655480

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Not yet reported National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 50 participants Est. completion 2027-12-31 1 site

Heart failure Other conditions: LVDD, Myocardial Fibrosis
View official trial listing →
Recruiting NCT NCT06659393

Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)

Novartis Pharmaceuticals 30 participants Est. completion 2027-11-30 28 sites

Heart failure
View official trial listing →
Recruiting NCT NCT06693674

Effect of Sacubitril-Valsartan on Cardiac Structure and Function

Not yet reported Mayo Clinic 45 participants Est. completion 2026-12 1 site

Other conditions: Congenital Heart Disease
View official trial listing →
Recruiting NCT NCT06704633

Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania

Not yet reported Martin Rohacek 298 participants Est. completion 2028-11-30 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT06917664

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Not yet reported China National Center for Cardiovascular Diseases 220 participants Est. completion 2027-06 1 site

Cardiovascular disease Other conditions: Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor
View official trial listing →
Recruiting NCT NCT07192341

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Not yet reported Kafrelsheikh University 220 participants Est. completion 2026-02-01 1 site

Heart failure Other conditions: Sacubitril/Valsartan, Prosthetic Heart Valve, Reduced Ejection Fraction
View official trial listing →
Recruiting NCT NCT07335900

A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

Not yet reported RenJi Hospital 25 participants Est. completion 2027-05-30 1 site

Other conditions: Severe Aortic Valve Stenosis
View official trial listing →
Recruiting NCT NCT07347925

Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF

Future University in Egypt 140 participants Est. completion 2026-05-01 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT07444398

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Not yet reported Khawaja Danish Ali 130 participants Est. completion 2026-03-31 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT07465653

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Not yet reported Novartis Pharmaceuticals 12 participants Est. completion 2026-09-24 6 sites

Heart failure
View official trial listing →
Recruiting NCT NCT07491718

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Not yet reported University of Edinburgh 100 participants Est. completion 2028-08-09 1 site

Other conditions: Takotsubo Cardiomyopathy
View official trial listing →
Recruiting NCT NCT07513883

The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

Not yet reported Ziekenhuis Oost-Limburg 100 participants Est. completion 2028-12 1 site

Heart failure
View official trial listing →
Recruiting NCT NCT07572032

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Not yet reported Kyungsub Song 80 participants Est. completion 2028-12-20 4 sites

Cardiovascular diseaseHeart failure Other conditions: Valvular Cardiomyopathy
View official trial listing →
Recruiting NCT NCT07631156

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

Not yet reported Kyungsub Song 80 participants Est. completion 2029-12-30 5 sites

Heart failure Other conditions: Ventricular Dysfunction, Left
View official trial listing →
Completed NCT NCT00549770

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 1334 participants Est. completion 2008-07 182 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT00887588

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Not yet reported Novartis Pharmaceuticals 307 participants Est. completion 2011-12 81 sites

Heart failure
View official trial listing →
Completed NCT NCT00913653

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

Not yet reported Novartis Pharmaceuticals 30 participants 1 site

Heart failure
View official trial listing →
Terminated NCT NCT01035255

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Not yet reported Novartis Pharmaceuticals 8442 participants Est. completion 2014-05 1031 sites

Heart failure
View official trial listing →
Completed NCT NCT01193101

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 389 participants Est. completion 2011-04 34 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01256411

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 341 participants Est. completion 2012-04 33 sites

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT01281306

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Not yet reported Novartis Pharmaceuticals 910 participants Est. completion 2011-12 90 sites

Other conditions: Systolic Hypertension
View official trial listing →
Completed NCT NCT01353508

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Not yet reported Novartis Pharmaceuticals 32 participants Est. completion 2012-08 1 site

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01569815

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Not yet reported Novartis Pharmaceuticals 32 participants Est. completion 2014-08 3 sites

Other conditions: Mild and Moderate Renal Impairment
View official trial listing →
Completed NCT NCT01569828

Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function

Not yet reported Novartis Pharmaceuticals 12 participants Est. completion 2009-09 3 sites

Other conditions: Pharmacokinetics, Renal Impaired, Healthy Volunteer
View official trial listing →
Completed NCT NCT01593787

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Not yet reported Novartis Pharmaceuticals 32 participants Est. completion 2013-03 13 sites

Other conditions: Hypertension With Renal Dysfunction
View official trial listing →
Completed NCT NCT01599104

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 1161 participants Est. completion 2013-04 61 sites

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT01601470

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

Not yet reported Novartis Pharmaceuticals 28 participants Est. completion 2013-01 1 site

Other conditions: Mild to Moderate Hypertension
View official trial listing →
Completed NCT NCT01615198

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 588 participants Est. completion 2013-07 79 sites

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT01621633

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Not yet reported Novartis Pharmaceuticals 32 participants Est. completion 2013-01 1 site

Other conditions: Hepatic Impairment
View official trial listing →
Completed NCT NCT01631864

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Not yet reported Novartis Pharmaceuticals 98 participants Est. completion 2013-07 3 sites

Other conditions: Hypertension, Concurrent Obesity
View official trial listing →
Completed NCT NCT01646671

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Not yet reported Novartis Pharmaceuticals 35 participants Est. completion 2013-02 9 sites

Other conditions: Severe Hypertension
View official trial listing →
Completed NCT NCT01663233

Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine

Not yet reported Novartis Pharmaceuticals 266 participants Est. completion 2013-05 28 sites

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT01681576

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Not yet reported Novartis Pharmaceuticals 72 participants Est. completion 2013-10 15 sites

Other conditions: Salt-sensitive Hypertension
View official trial listing →
Completed NCT NCT01692301

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Not yet reported Novartis Pharmaceuticals 454 participants Est. completion 2015-04 47 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01785472

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Not yet reported Novartis Pharmaceuticals 1438 participants Est. completion 2014-08 50 sites

Other conditions: Essential Hypertension
View official trial listing →
Withdrawn NCT NCT01865188

Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension

Not yet reported Novartis Pharmaceuticals Est. completion 2015-04

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01870739

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Not yet reported Novartis Pharmaceuticals 115 participants Est. completion 2015-06 4 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01876368

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Not yet reported Novartis Pharmaceuticals 376 participants Est. completion 2014-08 51 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT01920711

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Not yet reported Novartis Pharmaceuticals 4822 participants Est. completion 2019-06-07 715 sites

Heart failure
View official trial listing →
Completed NCT NCT01922089

Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

Not yet reported Novartis Pharmaceuticals 498 participants Est. completion 2014-08 105 sites

Heart failure
View official trial listing →
Completed NCT NCT02226120

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Not yet reported Novartis Pharmaceuticals 1980 participants Est. completion 2017-12-28 394 sites

Heart failure
View official trial listing →
No Longer Available NCT NCT02389933

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Novartis Pharmaceuticals 286 sites

Heart failure
View official trial listing →
Completed NCT NCT02468232

Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction

Not yet reported Novartis Pharmaceuticals 225 participants Est. completion 2021-02-18 49 sites

Heart failure
View official trial listing →
Completed NCT NCT02470403

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Not yet reported Novartis Pharmaceuticals 181 participants Est. completion 2016-04-04 1 site

Other conditions: Elevated Body Mass Index
View official trial listing →
Completed NCT NCT02554890

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

Not yet reported Novartis Pharmaceuticals 887 participants Est. completion 2018-07-24 123 sites

Heart failure
View official trial listing →
Terminated NCT NCT02636283

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

Not yet reported University of Minnesota 6 participants Est. completion 2018-11-01 1 site

Other conditions: Peripheral Arterial Disease
View official trial listing →
Completed NCT NCT02661217

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

Not yet reported Novartis Pharmaceuticals 1002 participants Est. completion 2018-06-20 152 sites

Heart failure
View official trial listing →
Completed NCT NCT02678312

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Not yet reported, Not yet reported Novartis Pharmaceuticals 393 participants Est. completion 2022-01-03 98 sites

Heart failure
View official trial listing →
Completed NCT NCT02687932

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Not yet reported Asan Medical Center 118 participants Est. completion 2018-01-02 4 sites

Other conditions: Mitral Valve Insufficiency, Left Ventricular Dysfunction
View official trial listing →
Completed NCT NCT02690974

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Not yet reported Novartis Pharmaceuticals 302 participants Est. completion 2017-11-29 32 sites

Other conditions: Hearth Failure With Reduced Ejection Fraction (HFrEF)
View official trial listing →
Completed NCT NCT02754518

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Not yet reported University of Chicago 40 participants Est. completion 2019-04 1 site

Heart failure
View official trial listing →
Completed NCT NCT02768298

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Not yet reported Novartis Pharmaceuticals 201 participants Est. completion 2019-11-25 34 sites

Heart failure
View official trial listing →
Terminated NCT NCT02787798

Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure

Not yet reported University Hospital, Toulouse 4 participants Est. completion 2018-01 1 site

Heart failure
View official trial listing →
Terminated NCT NCT02788656

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Not yet reported Brigham and Women's Hospital 4 participants Est. completion 2018-11-09 1 site

Heart failure
View official trial listing →
Completed NCT NCT02816736

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Not yet reported Duke University 365 participants Est. completion 2020-09-29 38 sites

Heart failure
View official trial listing →
Completed NCT NCT02874794

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Not yet reported Novartis Pharmaceuticals 465 participants Est. completion 2019-01-26 81 sites

Heart failure
View official trial listing →
Completed NCT NCT02884206

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Not yet reported Novartis Pharmaceuticals 592 participants Est. completion 2022-05-16 135 sites

Heart failure
View official trial listing →
Completed NCT NCT02887183

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Not yet reported Novartis Pharmaceuticals 794 participants Est. completion 2018-10-22 77 sites

Heart failure
View official trial listing →
Completed NCT NCT02900378

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Not yet reported Novartis Pharmaceuticals 621 participants Est. completion 2018-04-11 119 sites

Heart failure
View official trial listing →
Completed NCT NCT02916160

Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study

Not yet reported University Hospital, Montpellier 124 participants Est. completion 2020-02-27 6 sites

Heart failure Other conditions: Sleep Apnea Syndrome
View official trial listing →
Completed NCT NCT02924727

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Not yet reported Novartis Pharmaceuticals 5669 participants Est. completion 2021-02-26 486 sites

Cardiovascular disease
View official trial listing →
Completed NCT NCT02957409

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Novartis Pharmaceuticals 1009 participants Est. completion 2020-10-24 32 sites

Heart failure
View official trial listing →
Completed NCT NCT02970669

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Not yet reported Novartis Pharmaceuticals 140 participants Est. completion 2018-03-19 23 sites

Heart failure
View official trial listing →
Withdrawn NCT NCT03005184

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

Not yet reported Vanderbilt University Medical Center Est. completion 2020-01 1 site

Heart failure
View official trial listing →
Completed NCT NCT03066804

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Not yet reported Novartis Pharmaceuticals 2572 participants Est. completion 2019-10-28 380 sites

Heart failure
View official trial listing →
Withdrawn NCT NCT03119623

Comparing ARNI With ACE Inhibitor on Endothelial Function

Not yet reported Brigham and Women's Hospital Est. completion 2019-08

Heart failure
View official trial listing →
Completed NCT NCT03168568

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction

Not yet reported University of Zurich 79 participants Est. completion 2020-09-05 1 site

Heart failure
View official trial listing →
Completed NCT NCT03190304

The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure

Not yet reported University of Sao Paulo General Hospital 52 participants Est. completion 2020-09-23 1 site

Heart failure Other conditions: Exercise Tolerance, Vasodilation, Body Composition, Muscle Strength
View official trial listing →
Withdrawn NCT NCT03279861

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Not yet reported University of Maryland, Baltimore Est. completion 2019-11

Heart failure Other conditions: Hypertension
View official trial listing →
Completed NCT NCT03300427

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Not yet reported Novartis Pharmaceuticals 55 participants Est. completion 2022-03-23 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT03359967

Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment

Central Hospital, Izmir 24 participants Est. completion 2018-08-31

Heart failure
View official trial listing →
Completed NCT NCT03387163

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Novartis Pharmaceuticals 402 participants Est. completion 2019-06-21 1 site

Heart failure
View official trial listing →
Withdrawn NCT NCT03415906

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

Not yet reported Hannover Medical School Est. completion 2018-09-06 1 site

Heart failure
View official trial listing →
Completed NCT NCT03506412

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

Not yet reported Mayo Clinic 40 participants Est. completion 2021-03-23 1 site

Heart failure
View official trial listing →
Suspended NCT NCT03508739

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Not yet reported University of Pennsylvania 25 participants Est. completion 2026-06-30 1 site

Type 2 diabetes Other conditions: Pre-diabetic, Hypertension, Elevated Blood Pressure
View official trial listing →
Completed NCT NCT03552575

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Not yet reported NHS Greater Glasgow and Clyde 93 participants Est. completion 2020-07-25 2 sites

Heart failure
View official trial listing →
Status unknown NCT NCT03553303

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Not yet reported Oslo University Hospital 40 participants Est. completion 2022-05 1 site

Heart failure
View official trial listing →
Completed NCT NCT03553810

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Not yet reported National Heart Centre Singapore 80 participants Est. completion 2024-06-28 1 site

Other conditions: Hypertensive Heart Disease
View official trial listing →
Completed NCT NCT03647657

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

Not yet reported University Hospital, Basel, Switzerland 8 participants Est. completion 2021-12-14 1 site

Other conditions: Thyroid Cancer, Medullary
View official trial listing →
Completed NCT NCT03717688

The Effects of Neprilysin on Glucagon-like Peptide-1

Not yet reported Nicolai Jacob Wewer Albrechtsen 19 participants Est. completion 2019-05-14 1 site

Heart failure Other conditions: Diabetes
View official trial listing →
Terminated NCT NCT03738878

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Not yet reported Vanderbilt University Medical Center 4 participants Est. completion 2024-12-01 1 site

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT03744975

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Not yet reported Mayo Clinic 72 participants Est. completion 2025-08-27 1 site

Type 2 diabetes Other conditions: Diastolic Dysfunction
View official trial listing →
Completed NCT NCT03760588

Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Not yet reported Torbjorn Omland 138 participants Est. completion 2024-09-05 4 sites

Heart failure Other conditions: Breast Cancer Female
View official trial listing →
Status unknown NCT NCT03771729

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure

Not yet reported The Second Affiliated Hospital of Harbin Medical University 30 participants Est. completion 2019-06-15 Stand-alone

Chronic kidney disease
View official trial listing →
Completed NCT NCT03785405

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Not yet reported Novartis Pharmaceuticals 216 participants Est. completion 2023-12-29 79 sites

Heart failure
View official trial listing →
Status unknown NCT NCT03791723

Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation

Not yet reported The Second Affiliated Hospital of Chongqing Medical University 90 participants Est. completion 2021-12-30

Other conditions: Atrial Fibrillation, Cardiac Remodeling, Atrial, Sacubitril/Valsartan
View official trial listing →
Completed NCT NCT03816306

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

Mohammed Alnims 100 participants Est. completion 2019-12-01 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT03821701

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

Not yet reported First Affiliated Hospital Xi'an Jiaotong University 340 participants Est. completion 2022-01-31 1 site

Heart failure
View official trial listing →
Completed NCT NCT03830814

The Effects of Sacubitril/Valsartan on the Heart Functions

The Young Investigator Group of Cardiovascular Research 100 participants Est. completion 2018-07-31

Other conditions: Drug Effect
View official trial listing →
Completed NCT NCT03832660

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Not yet reported Newcastle University 168 participants Est. completion 2022-06-30 5 sites

Other conditions: Hypertrophic Cardiomyopathy
View official trial listing →
Completed NCT NCT03872778

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

Not yet reported, Not yet reported Advanced Accelerator Applications 35 participants Est. completion 2025-11-27 11 sites

Other conditions: Neoplasms
View official trial listing →
Completed NCT NCT03893435

The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction

Not yet reported The Young Investigator Group of Cardiovascular Research 192 participants Est. completion 2022-10-01 1 site

Cardiovascular disease
View official trial listing →
Completed NCT NCT03893526

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

Not yet reported University of Copenhagen 12 participants Est. completion 2021-03-01 1 site

Type 2 diabetes
View official trial listing →
Terminated NCT NCT03909295

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Not yet reported Novartis Pharmaceuticals 52 participants Est. completion 2019-11-19 17 sites

Heart failure
View official trial listing →
Completed NCT NCT03917459

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

Not yet reported Novartis Pharmaceuticals 27 participants Est. completion 2021-05-25 13 sites

Heart failure Other conditions: Erectile Dysfunction
View official trial listing →
Completed NCT NCT03928158

LCZ696 in Advanced LV Hypertrophy and HFpEF

Not yet reported National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 61 participants Est. completion 2023-12-31 1 site Stand-alone

Heart failure Other conditions: Essential Hypertension
View official trial listing →
Status unknown NCT NCT03935087

Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan

Azienda Ospedaliera Cardinale G. Panico 150 participants Est. completion 2019-06-30 6 sites

Heart failure
View official trial listing →
Active, not recruiting NCT NCT03938389

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

Not yet reported Ohio State University 90 participants Est. completion 2026-06 1 site

Prediabetes Other conditions: Obesity, Blood Pressure
View official trial listing →
Completed NCT NCT03988634

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Not yet reported Novartis Pharmaceuticals 467 participants Est. completion 2022-12-14 97 sites

Heart failure
View official trial listing →
Completed NCT NCT04023227

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Not yet reported Novartis Pharmaceuticals 922 participants Est. completion 2025-03-31 79 sites

Heart failure Other conditions: Chagas Disease
View official trial listing →
Status unknown NCT NCT04092309

Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation

Not yet reported University of Athens 90 participants Est. completion 2021-09-01 1 site

Other conditions: Hematopoietic Stem Cell Transplantation, Cardiotoxicity
View official trial listing →
Status unknown NCT NCT04103554

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients

Not yet reported University of Zagreb 60 participants Est. completion 2025-02 6 sites

Heart failure
View official trial listing →
Status unknown NCT NCT04107220

Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure

Not yet reported Unity Health Toronto 300 participants Est. completion 2020-06 1 site

Heart failure
View official trial listing →
Completed NCT NCT04113109

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Not yet reported Vanderbilt University Medical Center 46 participants Est. completion 2025-07-30 1 site Stand-alone

Heart failure
View official trial listing →
Withdrawn NCT NCT04128891

Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

Not yet reported Flinders University Est. completion 2024-02-01

Heart failure
View official trial listing →
Status unknown NCT NCT04133428

Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 100 participants Est. completion 2021-07-15 1 site

Heart failure
View official trial listing →
Completed NCT NCT04141800

Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction

Spanish Society of Cardiology 565 participants Est. completion 2021-03-31 1 site

Heart failure Other conditions: Hyperkalemia
View official trial listing →
Terminated NCT NCT04149990

Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI

Not yet reported Jacob Moller 51 participants Est. completion 2023-06-06 2 sites

Cardiovascular disease Other conditions: Diastolic Dysfunction
View official trial listing →
Completed NCT NCT04153136

The ENCHANTMENT HIV Study

Not yet reported Massachusetts General Hospital 39 participants Est. completion 2025-07-09 1 site

Heart failure Other conditions: HIV/AIDS
View official trial listing →
Completed NCT NCT04164732

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Not yet reported Novartis Pharmaceuticals 46 participants Est. completion 2023-08-22 18 sites

Other conditions: Cardiomyopathy, Hypertrophic
View official trial listing →
Status unknown NCT NCT04185103

Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 20 participants Est. completion 2020-12-15 4 sites

Heart failure
View official trial listing →
Status unknown NCT NCT04197050

Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD

Not yet reported RenJi Hospital 60 participants Est. completion 2022-11 1 site

Other conditions: Myocardial Injury, Connective Tissue Diseases
View official trial listing →
Withdrawn NCT NCT04206865

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output

Not yet reported The Cleveland Clinic Est. completion 2020-09-10 1 site

Other conditions: Cardiogenic Shock
View official trial listing →
Status unknown NCT NCT04217135

The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

Not yet reported Kaohsiung Veterans General Hospital. 400 participants Est. completion 2022-07-31 1 site

Heart failure Other conditions: Mitral Regurgitation
View official trial listing →
Completed NCT NCT04218435

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

Clinision 200 participants Est. completion 2020-12-30 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04342351

Early Treatment of ARNI on Myocardial Remodeling and Progress

Not yet reported RenJi Hospital 280 participants Est. completion 2021-12-30 1 site

Cardiovascular disease
View official trial listing →
Completed NCT NCT04397302

Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction

Italian Society of Cardiology 652 participants Est. completion 2020-03-16 1 site

Heart failure Other conditions: Left Ventricular Dysfunction, Ventricular Remodeling
View official trial listing →
Completed NCT NCT04434170

Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure

Centro Cardiologico Monzino 112 participants Est. completion 2021-12-15 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04458285

Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure

Not yet reported Guangdong Provincial People's Hospital 118 participants Est. completion 2020-12-31 1 site

Heart failure Other conditions: Hemodialysis Complication
View official trial listing →
Completed NCT NCT04467931

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

University of Utah 22213 participants Est. completion 2020-12-31 1 site

Other conditions: Hypertension, COVID
View official trial listing →
Terminated NCT NCT04491136

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)

Not yet reported Novartis Pharmaceuticals 201 participants Est. completion 2023-06-08 23 sites

Heart failure
View official trial listing →
Completed NCT NCT04498780

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure

University of Leipzig 117 participants Est. completion 2026-04-08 2 sites

Heart failure
View official trial listing →
Status unknown NCT NCT04572724

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Not yet reported Shenzhen Second People's Hospital 120 participants Est. completion 2023-06 1 site

Heart failure Other conditions: Peritoneal Dialysis Complication, Hemodialysis Complication
View official trial listing →
Completed NCT NCT04575675

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Not yet reported Cheng-Hsin General Hospital 78 participants Est. completion 2020-12-30 1 site

Heart failure Other conditions: Hypotension
View official trial listing →
Completed NCT NCT04587947

Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Not yet reported St. Josefs-Hospital Wiesbaden GmbH 63 participants Est. completion 2022-05-31 1 site

Heart failure
View official trial listing →
Completed NCT NCT04637152

Sacubitril/Valsartan in Resistant Hypertension

Not yet reported Hospital Geral Roberto Santos 80 participants Est. completion 2022-08-17 2 sites

Other conditions: Resistant Hypertension, Blood Pressure
View official trial listing →
Withdrawn NCT NCT04637555

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Not yet reported Novartis Pharmaceuticals Est. completion 2023-06-01

Cardiovascular disease
View official trial listing →
Completed NCT NCT04649229

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Not yet reported Yale University 46 participants Est. completion 2025-05-22 1 site Stand-alone

Heart failure
View official trial listing →
Status unknown NCT NCT04687111

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Not yet reported Mark Ledwidge 250 participants Est. completion 2021-06-11 2 sites

Other conditions: Atrial Remodeling, Myocardial Dysfunction, Left Ventricular Remodeling, Left Ventricular Diastolic Dysfunction, Hypertension, Cardiovascular Morbidity, Fibrosis Myocardial, Inflammatory Myopathy, Atrial Arrhythmia
View official trial listing →
Completed NCT NCT04688294

The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure

Not yet reported Amir Safwat 60 participants Est. completion 2021-07-01 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04707261

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Not yet reported Xiangtan Central Hospital 1990 participants Est. completion 2026-01-01 1 site

Heart failure Other conditions: Anemia
View official trial listing →
Completed NCT NCT04735354

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Novartis Pharmaceuticals 268 participants Est. completion 2022-06-01 1 site

Heart failure
View official trial listing →
Completed NCT NCT04736433

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

Brigham and Women's Hospital 6066 participants Est. completion 2021-02-18 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04743063

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Brigham and Women's Hospital 40000 participants Est. completion 2022-12-31 1 site

Heart failure Other conditions: Frailty
View official trial listing →
Completed NCT NCT04753112

Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device

Not yet reported Germans Trias i Pujol Hospital 14 participants Est. completion 2021-09-20 1 site

Other conditions: Pulmonary Hypertension
View official trial listing →
Completed NCT NCT04781881

Special Drug Use Surveillance for Entresto Tablets

Novartis Pharmaceuticals 688 participants Est. completion 2023-04-21 121 sites

Heart failure
View official trial listing →
Status unknown NCT NCT04800081

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Not yet reported LanZhou University 264 participants Est. completion 2021-07-09 1 site

Other conditions: Hypertension
View official trial listing →
Status unknown NCT NCT04803175

Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction

Samsung Medical Center 100 participants Est. completion 2025-02 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04853758

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

Not yet reported University of Sao Paulo General Hospital 200 participants Est. completion 2024-12-01 1 site

Other conditions: Chagas Cardiomyopathy
View official trial listing →
Withdrawn NCT NCT04872959

TRANSFORM Heart Failure with Reduced Ejection Fraction

Not yet reported Massachusetts General Hospital Est. completion 2024-05

Heart failure
View official trial listing →
Completed NCT NCT04883528

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

Not yet reported, Not yet reported Duke University 42 participants Est. completion 2023-06-13 1 site

Other conditions: Covid19
View official trial listing →
Status unknown NCT NCT04912167

The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Not yet reported West China Hospital 376 participants Est. completion 2026-06 1 site

Other conditions: STEMI
View official trial listing →
Status unknown NCT NCT04929600

Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

Not yet reported Shanghai Jiao Tong University School of Medicine 120 participants Est. completion 2023-12 1 site

Other conditions: Hypertension, Left Ventricular Hypertrophy
View official trial listing →
Completed NCT NCT05021419

Efficacy of a Streamlined Heart Failure Optimization Protocol

Not yet reported The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust 60 participants Est. completion 2024-01-07 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT05053893

Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

Not yet reported The Affiliated Hospital of Qingdao University 40 participants Est. completion 2022-09-01 1 site

Other conditions: Cardio-Renal Syndrome
View official trial listing →
Status unknown NCT NCT05060588

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Not yet reported Qingdao Central Hospital 200 participants Est. completion 2023-02 1 site

Cardiovascular disease Other conditions: Hypertension
View official trial listing →
Status unknown NCT NCT05089539

The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF

Not yet reported Chongqing Medical University 60 participants Est. completion 2022-04-01 1 site

Heart failure
View official trial listing →
Completed NCT NCT05096039

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Novartis Pharmaceuticals 1614719 participants Est. completion 2020-09-30 1 site

Heart failure
View official trial listing →
Completed NCT NCT05096143

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Novartis Pharmaceuticals 42269 participants Est. completion 2020-10-19 1 site

Heart failure
View official trial listing →
Terminated NCT NCT05117736

ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

Not yet reported Montreal Heart Institute 15 participants Est. completion 2023-03-12 1 site

Heart failure Other conditions: Systemic Right Ventricle
View official trial listing →
Status unknown NCT NCT05164653

Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Not yet reported Saga University 400 participants Est. completion 2025-03 1 site

Heart failure
View official trial listing →
Completed NCT NCT05168787

Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

Methodist Health System 6558 participants Est. completion 2025-07-08 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT05212597

Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

Not yet reported Samsung Medical Center 100 participants Est. completion 2024-12 1 site

Other conditions: Aortic Valve Insufficiency
View official trial listing →
Completed NCT NCT05243199

Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Not yet reported Ruijin Hospital 330 participants Est. completion 2023-03-08 1 site

Chronic kidney diseaseHeart failure
View official trial listing →
Enrolling by invitation NCT NCT05279742

Enhancing the Natriuretic Peptide System in HFpEF

Not yet reported, Not yet reported Horng Chen 60 participants Est. completion 2027-04 1 site

Heart failureChronic kidney disease
View official trial listing →
Completed NCT NCT05348226

The ENVI Study: Effect of Entresto on Left Ventricular Remodelling on Cardiac MRI

University Hospital Southampton NHS Foundation Trust 50 participants Est. completion 2023-03-23 1 site

Heart failure
View official trial listing →
Completed NCT NCT05353166

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Not yet reported Regeneron Pharmaceuticals 59 participants Est. completion 2025-06-02 1 site

Heart failure
View official trial listing →
Completed NCT NCT05366101

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

Not yet reported, Not yet reported Newcastle-upon-Tyne Hospitals NHS Trust 168 participants Est. completion 2022-03-31 1 site

Other conditions: Hypertrophic Cardiomyopathy
View official trial listing →
Completed NCT NCT05387967

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Not yet reported National Institute of Cardiovascular Diseases, Pakistan 121 participants Est. completion 2021-09-30 1 site

Heart failure
View official trial listing →
Completed NCT NCT05448872

Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

Novartis Pharmaceuticals 924 participants Est. completion 2021-09-15 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT05487261

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

Not yet reported Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań 260 participants Est. completion 2025-11 5 sites

Heart failure
View official trial listing →
Completed NCT NCT05498181

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Not yet reported Brigham and Women's Hospital 45 participants Est. completion 2026-01-31 1 site

Other conditions: Hemodialysis
View official trial listing →
Completed NCT NCT05528419

Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Not yet reported Shanghai Jiao Tong University School of Medicine 320 participants Est. completion 2026-02-01 1 site

Other conditions: Atrial Fibrillation Recurrent, Hypertension
View official trial listing →
Status unknown NCT NCT05545059

Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 138 participants Est. completion 2023-03-31 1 site

Other conditions: Resistant Hypertension
View official trial listing →
Status unknown NCT NCT05580510

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Not yet reported, Not yet reported Instituto Nacional de Cardiologia Ignacio Chavez 160 participants Est. completion 2024-03-29 1 site

Heart failure Other conditions: Congenital Heart Disease
View official trial listing →
Completed NCT NCT05613140

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Novartis Pharmaceuticals 9230 participants Est. completion 2021-11-05 1 site

Heart failure
View official trial listing →
Completed NCT NCT05636774

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

Not yet reported University Hospital, Essen 97 participants Est. completion 2025-03-01 1 site

Other conditions: Patients With Advanced Cancer Receiving Specialized Palliative Care
View official trial listing →
Active, not recruiting NCT NCT05637853

Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

Not yet reported Göteborg University 60 participants Est. completion 2026-08-26 1 site

Heart failure
View official trial listing →
Completed NCT NCT05848206

Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

Novartis Pharmaceuticals 251831 participants Est. completion 2022-04-29 1 site

Heart failure
View official trial listing →
Withdrawn NCT NCT05870709

Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure

Novartis Pharmaceuticals Est. completion 2024-10-31

Heart failure
View official trial listing →
Completed NCT NCT05881720

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Not yet reported Damanhour University 80 participants Est. completion 2023-06-19 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT05892146

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

Not yet reported National Cheng-Kung University Hospital 100 participants Est. completion 2025-12-31 1 site

Heart failure Other conditions: Chemotherapeutic Toxicity, Cardiotoxicity, Breast Cancer, Lymphoma
View official trial listing →
Status unknown NCT NCT05934071

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 160 participants Est. completion 2024-12-31 1 site

Heart failure Other conditions: Ventricular Remodeling, Ventricular Dysfunction
View official trial listing →
Completed NCT NCT05963282

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

Novartis Pharmaceuticals 9870 participants Est. completion 2022-07-19 1 site

Heart failure
View official trial listing →
Completed NCT NCT05976230

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

Novartis Pharmaceuticals 1125 participants Est. completion 2025-05-29 117 sites

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT05989503

Initiation of ARNi and SGLT2i in Patients With HFrEF

Not yet reported Universidade do Porto 62 participants Est. completion 2025-07-31 5 sites

Heart failure
View official trial listing →
Completed NCT NCT05991284

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

Not yet reported Ziekenhuis Oost-Limburg 84 participants Est. completion 2026-05-09 1 site

Heart failure Other conditions: Functional Mitral Regurgitation
View official trial listing →
Completed NCT NCT06029712

Heart Failure Polypill at a Safety Net Hospital

Not yet reported University of California, San Francisco 35 participants Est. completion 2025-01-29 1 site

Heart failure Other conditions: HIV Infections
View official trial listing →
Status unknown NCT NCT06035978

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Not yet reported University Hospital Ostrava 100 participants Est. completion 2026-04 1 site

Cardiovascular diseaseHeart failure
View official trial listing →
Completed NCT NCT06090487

Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance

Not yet reported Ain Shams University 30 participants Est. completion 2024-03-01 1 site

Heart failure
View official trial listing →
Terminated NCT NCT06142383

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Not yet reported Novartis Pharmaceuticals 136 participants Est. completion 2024-11-01 62 sites

Heart failure
View official trial listing →
Completed NCT NCT06149104

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Not yet reported Novartis Pharmaceuticals 8 participants Est. completion 2024-08-14 6 sites

Heart failure
View official trial listing →
Status unknown NCT NCT06149806

National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan

University Hospital, Grenoble 50 participants Est. completion 2025-12 1 site

Other conditions: Complex Congenital Heart Disease
View official trial listing →
Status unknown NCT NCT06193187

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Not yet reported Dr. Reddy's Laboratories (Thailand) Limited 48 participants Est. completion 2024-08 1 site

Other conditions: Healthy Volunteers
View official trial listing →
Completed NCT NCT06236061

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Not yet reported Novartis Pharmaceuticals 718 participants Est. completion 2025-12-23 43 sites

Other conditions: Hypertension
View official trial listing →
Terminated NCT NCT06237309

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Not yet reported Regeneron Pharmaceuticals 89 participants Est. completion 2025-12-29 44 sites

Heart failure
View official trial listing →
Status unknown NCT NCT06248112

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Not yet reported Bio-innova Co., Ltd 40 participants Est. completion 2024-07-06

Other conditions: Healthy Subjects
View official trial listing →
Status unknown NCT NCT06266988

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Not yet reported Viatris Inc. 48 participants Est. completion 2024-08

Heart failure
View official trial listing →
Status unknown NCT NCT06273254

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Not yet reported Viatris Inc. 48 participants Est. completion 2024-09 1 site

Other conditions: Bioequivalence Study
View official trial listing →
Completed NCT NCT06357104

Detoxification From the Lipid Tract

Not yet reported Pachankis, Yang I., M.D. 1 participants Est. completion 2024-03-20 1 site

Other conditions: COVID-19 Vaccine Adverse Reaction
View official trial listing →
Status unknown NCT NCT06439069

BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients

Lithuanian University of Health Sciences 340 participants Est. completion 2024-12-01 1 site

Heart failure Other conditions: Obesity
View official trial listing →
Status unknown NCT NCT06501651

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Not yet reported Sichuan Academy of Medical Sciences 297 participants Est. completion 2025-04-10 1 site

Type 2 diabetes Other conditions: Essential Hypertension, Nephropathy
View official trial listing →
Withdrawn NCT NCT06536309

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

Not yet reported Brigham and Women's Hospital Est. completion 2026-08-27

Heart failure Other conditions: Myocardial Fibrosis
View official trial listing →
Completed NCT NCT06604897

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

Novartis Pharmaceuticals 1405 participants Est. completion 2025-10-31 1 site

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT06697353

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

Bayer 4936 participants Est. completion 2025-09-19 1 site

Heart failure
View official trial listing →
Not yet recruiting NCT NCT06712030

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Not yet reported Puerta de Hierro University Hospital 114 participants Est. completion 2027-06 1 site

Other conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
View official trial listing →
Not yet recruiting NCT NCT06716970

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Not yet reported Wuhan Createrna Science and Technology Co., Ltd 810 participants Est. completion 2027-02-28 1 site

Other conditions: Essential Hypertension
View official trial listing →
Not yet recruiting NCT NCT06900803

Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)

Not yet reported National Taiwan University Hospital 200 participants Est. completion 2027-10-31

Heart failure Other conditions: Sacubitril/Valsartan, Medication Adherence
View official trial listing →
Completed NCT NCT06922253

Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)

Not yet reported Humanis Saglık Anonim Sirketi 48 participants Est. completion 2025-03-17 1 site

Heart failure
View official trial listing →
Completed NCT NCT07023016

Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

Not yet reported, Not yet reported National Heart Institute, Egypt 515 participants Est. completion 2025-02-28 2 sites

Heart failureChronic kidney disease
View official trial listing →
Completed NCT NCT07088471

Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan

Connolly Hospital Blanchardstown 334 participants Est. completion 2025-08-01 1 site

Heart failure
View official trial listing →
Completed NCT NCT07130175

Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)

Not yet reported Qian Feng 118 participants Est. completion 2024-12-31 1 site

Heart failure Other conditions: Polymorphic Ventricular Tachycardia
View official trial listing →
Not yet recruiting NCT NCT07157527

Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF

Assiut University 70 participants Est. completion 2027-12-30

Other conditions: Left Ventricular Diastolic Function
View official trial listing →
Not yet recruiting NCT NCT07197372

Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy

Assiut University 70 participants Est. completion 2027-12-30

Other conditions: ARNI, Pediatric Dilated Cardiomyopathy, ACE Inhibitor
View official trial listing →
Not yet recruiting NCT NCT07232966

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

Not yet reported Yan Li 220 participants Est. completion 2029-06-30 1 site

Other conditions: Resistant Hypertension
View official trial listing →
Not yet recruiting NCT NCT07241338

Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

Not yet reported Jing Liu 104 participants Est. completion 2027-06 1 site

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT07341893

Sacubitril-valsartan in Patients With Heart Failure.

Not yet reported Damanhour University 60 participants Est. completion 2026-03-30 1 site

Heart failure
View official trial listing →
Completed NCT NCT07376265

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

Novartis Pharmaceuticals 1249 participants Est. completion 2024-04-11 1 site

Heart failure
View official trial listing →
Completed NCT NCT07379788

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Not yet reported Rehab Werida 180 participants Est. completion 2026-03-01 1 site

Heart failure
View official trial listing →
Completed NCT NCT07417215

The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

Not yet reported University Clinical Hospital Mostar 52 participants Est. completion 2026-05-10 1 site

Heart failure Other conditions: Hemodialysis, Sacubitril/Valsartan
View official trial listing →
Not yet recruiting NCT NCT07465666

A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Novartis Pharmaceuticals 500 participants Est. completion 2027-08-15

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT07465679

A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan

Novartis Pharmaceuticals 2508 participants Est. completion 2026-03-10 1 site

Heart failure
View official trial listing →
Not yet recruiting NCT NCT07486453

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 60 participants Est. completion 2026-04-25 1 site

Other conditions: Primary Hypertension
View official trial listing →
Completed NCT NCT07527767

Secondary Use of PARALLEL-HF Data

Novartis Pharmaceuticals 236 participants Est. completion 2023-12-15 1 site

Heart failure
View official trial listing →
Completed NCT NCT07700875

A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

Not yet reported Wuhan Createrna Science and Technology Co., Ltd 391 participants Est. completion 2023-09-11 1 site

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT07704684

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 376 participants Est. completion 2025-09-08 1 site

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT07704697

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 346 participants Est. completion 2025-11-24 1 site

Other conditions: Essential Hypertension
View official trial listing →
Completed NCT NCT07746908

Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet.

Not yet reported Center for Bioequivalence Studies and Clinical Research 60 participants Est. completion 2025-07-18 1 site

Other conditions: Healthy Participants
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03744975

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.